-
Mashup Score: 10The Landmark Series: Cancer Vaccines for Solid Tumors - 1 day(s) ago
Annals of Surgical Oncology – Immunotherapy has become an integral part of the treatment for solid tumors. Cancer vaccines represent a potentially powerful class of immunotherapeutic agents to…
Source: link.springer.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0AKT kinases as therapeutic targets - Journal of Experimental & Clinical Cancer Research - 22 day(s) ago
AKT, or protein kinase B, is a central node of the PI3K signaling pathway that is pivotal for a range of normal cellular physiologies that also underlie several pathological conditions, including inflammatory and autoimmune diseases, overgrowth syndromes, and neoplastic transformation. These pathologies, notably cancer, arise if either the activity of AKT or its positive or negative upstream or downstream regulators or effectors goes unchecked, superimposed on by its intersection with a slew of other pathways. Targeting the PI3K/AKT pathway is, therefore, a prudent countermeasure. AKT inhibitors have been tested in many clinical trials, primarily in combination with other drugs. While some have recently garnered attention for their favorable profile, concern over resistance and off-target effects have continued to hinder their widespread adoption in the clinic, mandating a discussion on alternative modes of targeting. In this review, we discuss isoform-centric targeting that may be mor
Source: jeccr.biomedcentral.comCategories: General Medicine News, Oncologists1Tweet-
Our #TranslationalMedicine link of the week, chosen by @SWOG's @recnac1 & Jimmy Rae, PhD: "AKT Kinases as Therapeutic Targets" in J Exp Clin Cancer Res https://t.co/mwlhRj2sVT https://t.co/SeOuTsqH8b
-
-
Mashup Score: 4Pharmacological and Biological Targeting of FGFR1 in Cancer - 29 day(s) ago
FGFR1 is a key member of the fibroblast growth factor receptor family, mediating critical signaling pathways such as RAS-MAPK and PI3K-AKT. which are integral to regulating essential cellular processes, including proliferation, differentiation, and survival. Alterations in FGFR1 can lead to constitutive activation of signaling pathways that drive oncogenesis by promoting uncontrolled cell division, inhibiting apoptosis, and enhancing the metastatic potential of cancer cells. This article reviews the activation mechanisms and signaling pathways of FGFR1 and provides a detailed exposition of the types of FGFR1 aberration. Furthermore, we have compiled a comprehensive overview of current therapies targeting FGFR1 aberration in cancer, aiming to offer new perspectives for future cancer treatments by focusing on drugs that address specific FGFR1 alterations.
Source: www.mdpi.comCategories: General Medicine News, Oncologists1Tweet-
Our #TranslationalMedicine link of the week, chosen by @SWOG's @recnac1 & Jimmy Rae, PhD: Pharmacological and Biological Targeting of FGFR1 in Cancer https://t.co/TKirY3atuJ https://t.co/eNjovRDipV
-
-
Mashup Score: 11The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development - 1 month(s) ago
Abstract. Antibody–drug conjugates (ADC) represent one of the most rapidly expanding treatment modalities in oncology, with 11 ADCs approved by the FDA and more than 210 currently being tested in clinical trials. Spanning over 40 years, ADC clinical development has enhanced our understanding of the multifaceted mechanisms of action for this class of therapeutics. In this article, we discuss key insights into the toxicity, efficacy, stability, distribution, and fate of ADCs. Furthermore, we highlight ongoing challenges related to their clinical optimization, the development of rational sequencing strategies, and the identification of predictive biomarkers.Significance: The development and utilization of ADCs have allowed for relevant improvements in the prognosis of multiple cancer types. Concomitantly, the rise of ADCs in oncology has produced several challenges, including the prediction of their activity, their utilization in sequence, and minimization of their side effects, that stil
Source: aacrjournals.orgCategories: General Medicine News, Oncologists1Tweet-
Our #TranslationalMedicine link of the week, chosen by @SWOG's @recnac1 & Jimmy Rae, PhD: The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development in Cancer Discovery; 14:2089-2108, Nov 2024 https://t.co/yUMX7FK7Ha https://t.co/hbeMM0zokn
-
-
Mashup Score: 11The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development - 1 month(s) ago
Abstract. Antibody–drug conjugates (ADC) represent one of the most rapidly expanding treatment modalities in oncology, with 11 ADCs approved by the FDA and more than 210 currently being tested in clinical trials. Spanning over 40 years, ADC clinical development has enhanced our understanding of the multifaceted mechanisms of action for this class of therapeutics. In this article, we discuss key insights into the toxicity, efficacy, stability, distribution, and fate of ADCs. Furthermore, we highlight ongoing challenges related to their clinical optimization, the development of rational sequencing strategies, and the identification of predictive biomarkers.Significance: The development and utilization of ADCs have allowed for relevant improvements in the prognosis of multiple cancer types. Concomitantly, the rise of ADCs in oncology has produced several challenges, including the prediction of their activity, their utilization in sequence, and minimization of their side effects, that stil
Source: aacrjournals.orgCategories: General Medicine News, Oncologists1Tweet-
Our #TranslationalMedicine link of the week, chosen by @SWOG's @recnac1 & Jimmy Rae, PhD: The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development in Cancer Discovery; 14:2089-2108, Nov 2024 https://t.co/yUMX7FK7Ha https://t.co/hbeMM0zokn
-
-
Mashup Score: 7The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development - 2 month(s) ago
Abstract. Antibody–drug conjugates (ADC) represent one of the most rapidly expanding treatment modalities in oncology, with 11 ADCs approved by the FDA and more than 210 currently being tested in clinical trials. Spanning over 40 years, ADC clinical development has enhanced our understanding of the multifaceted mechanisms of action for this class of therapeutics. In this article, we discuss key insights into the toxicity, efficacy, stability, distribution, and fate of ADCs. Furthermore, we highlight ongoing challenges related to their clinical optimization, the development of rational sequencing strategies, and the identification of predictive biomarkers.Significance: The development and utilization of ADCs have allowed for relevant improvements in the prognosis of multiple cancer types. Concomitantly, the rise of ADCs in oncology has produced several challenges, including the prediction of their activity, their utilization in sequence, and minimization of their side effects, that stil
Source: aacrjournals.orgCategories: General Medicine News, Oncologists1Tweet-
Our #TranslationalMedicine link of the week, chosen by @SWOG's @recnac1 & Jimmy Rae, PhD: The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development in Cancer Discovery; 14:2089-2108, Nov 2024 https://t.co/yUMX7FK7Ha https://t.co/hbeMM0zokn
-
-
Mashup Score: 1Ten challenges and opportunities in computational immuno-oncology - 2 month(s) ago
Immuno-oncology has transformed the treatment of cancer, with several immunotherapies becoming the standard treatment across histologies. Despite these advancements, the majority of patients do not experience durable clinical benefits, highlighting the imperative for ongoing advancement in immuno-oncology. Computational immuno-oncology emerges as a forefront discipline that draws on biomedical data science and intersects with oncology, immunology, and clinical research, with the overarching goal to accelerate the development of effective and safe immuno-oncology treatments from the laboratory to the clinic. In this review, we outline 10 critical challenges and opportunities in computational immuno-oncology, emphasizing the importance of robust computational strategies and interdisciplinary collaborations amid the constantly evolving interplay between clinical needs and technological innovation.
Source: jitc.bmj.comCategories: General Medicine News, Onc News and JournalsTweet-
Our #TranslationalMedicine link of the week, chosen by @SWOG's @recnac1 & Jimmy Rae, PhD: Ten Challenges and Opportunities in Computational Immuno-Oncology https://t.co/f8dqw8WfK3 https://t.co/XHy6P9zExQ
-
-
Mashup Score: 0
Cancer and Metastasis Reviews – Immune checkpoint inhibitors have shaped the landscape of cancer treatment. However, many patients either do not respond or suffer from later progression. Numerous…
Source: link.springer.comCategories: General Medicine News, Oncologists1Tweet-
Our #TranslationalMedicine links of the week (2nd of 2), chosen by @SWOG's @recnac1 & Jimmy Rae, PhD: Tumor Necrosis Factor Superfamily Signaling: Life and Death in Cancer https://t.co/5K86bO2xLn https://t.co/wFewTNC1qj
-
-
Mashup Score: 0
Cancer and Metastasis Reviews – Immune checkpoint inhibitors have shaped the landscape of cancer treatment. However, many patients either do not respond or suffer from later progression. Numerous…
Source: link.springer.comCategories: General Medicine News, Oncologists1Tweet-
Our #TranslationalMedicine links of the week (2nd of 2), chosen by @SWOG's @recnac1 & Jimmy Rae, PhD: Tumor Necrosis Factor Superfamily Signaling: Life and Death in Cancer https://t.co/5K86bO2xLn https://t.co/wFewTNC1qj
-
-
Mashup Score: 0
Cancer and Metastasis Reviews – Immune checkpoint inhibitors have shaped the landscape of cancer treatment. However, many patients either do not respond or suffer from later progression. Numerous…
Source: link.springer.comCategories: General Medicine News, Oncologists1Tweet-
Our #TranslationalMedicine links of the week (2nd of 2), chosen by @SWOG's @recnac1 & Jimmy Rae, PhD: Tumor Necrosis Factor Superfamily Signaling: Life and Death in Cancer https://t.co/5K86bO2xLn https://t.co/wFewTNC1qj
-
Our #TranslationalMedicine link of the week, chosen by @SWOG's @recnac1 & Jimmy Rae, PhD: The Landmark Series: Cancer Vaccines for Solid Tumors https://t.co/LbU7p7XCO2 https://t.co/llA0CMfICl